EBITDA at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s EBITDA?
- ARS Pharmaceuticals, Inc. (SPRY) reported EBITDA of -$59.75M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s EBITDA changed year-over-year?
- ARS Pharmaceuticals, Inc.'s EBITDA decreased by 61.9% year-over-year, from -$36.9M to -$59.75M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s EBITDA?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s EBITDA has grown at a 71.9% compound annual growth rate (CAGR), from -$35.07M to -$178.08M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.